This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Mephedrone (4 - methylmethcathinone)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Mephedrone (4-methylmethcathinone) - colloquially known as 'Miaow,' '4-MMC,'Meph,' and 'TopCat'

  • is believed to act by stimulating the release of monoamine neurotransmitters and inhibit their reuptake

  • is a synthetic stimulant that is chemically related to cathinone, the psychoactive chemical class present in the khat plant

  • drug causes euphoria, sexual stimulation, stimulus-enhanced appreciation for music, and similar effects to cocaine, amphetamines, and MDMA

  • also causes hallucinations, anxiety, paranoia and other delusions, seizures, poor concentration, poor short-term memory, teeth grinding, raised blood pressure, dilated pupils, and seizures

  • can be taken orally, snorted, or intravenously administered

  • several deaths from effects of the drug have been reported in Europe
    • Stimulant related deaths typically result from a sympathomimetic toxidrome - a constellation of symptoms and signs that can be seen with excessive consumption of stimulant type drugs - accompanied by cardiac conduction problems, cerebral haemorrhage, and sometimes hyperpyrexia

  • available in the form of tablets, capsules, or white powder. Snorting is the most common route of drug use, and the intravenous the least used

Mephedrone was classified as a Class B drug in the UK in 2010.

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.